This article has been updated to correct information about Nucleix's partnership with the MD Anderson Cancer Center.
NEW YORK — Israeli cancer diagnostics developer Nucleix said on Wednesday that it raised $22 million in December, extending a financing round closed earlier last year.
The additional investment was led by Sands Capital and follows a $55 million oversubscribed financing round Nucleix closed in April, bringing the total amount raised by the firm in 2021 to $77 million.
Nucleix is developing liquid biopsy tests for early-stage and recurring cancer diagnosis that use PCR and next-generation sequencing technologies to detect tissue-specific methylation patterns on circulating tumor DNA that can be analyzed using proprietary software.
The company currently markets a bladder cancer recurrence test — called Bladder EpiCheck — in Europe and is awaiting 510(k) clearance from the US Food and Drug Administration for the assay. It has also developed a lung cancer early detection test, called Lung EpiCheck, and is working on another lung cancer test that uses the EpiCheck platform in partnership with the MD Anderson Cancer Center.